| Literature DB >> 30451148 |
Valentina Aria1, Joseph T P Yeeles2.
Abstract
DNA replication commences at eukaryotic replication origins following assembly and activation of bidirectional CMG helicases. Once activated, CMG unwinds the parental DNA duplex and DNA polymerase α-primase initiates synthesis on both template strands. By utilizing an origin-dependent replication system using purified yeast proteins, we have mapped start sites for leading-strand replication. Synthesis is mostly initiated outside the origin sequence. Strikingly, rightward leading strands are primed left of the origin and vice versa. We show that each leading strand is established from a lagging-strand primer synthesized by the replisome on the opposite side of the origin. Preventing elongation of primers synthesized left of the origin blocked rightward leading strands, demonstrating that replisomes are interdependent for leading-strand synthesis establishment. The mechanism we reveal negates the need for dedicated leading-strand priming and necessitates a crucial role for the lagging-strand polymerase Pol δ in connecting the nascent leading strand with the advancing replisome.Entities:
Keywords: CMG helicase; DNA polymerase; DNA replication; leading-strand synthesis; primase; priming; replication fork; replication origin; replisome
Year: 2018 PMID: 30451148 PMCID: PMC6344338 DOI: 10.1016/j.molcel.2018.10.019
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970
Figure 1Pol εPIP Replisomes Are Dependent on Pol δ
(A) Diagram illustrating two non-mutually exclusive pathways for connecting the 3ʹ end of the nascent leading strand to CMGE after primer synthesis by Pol α.
(B) Primer extension reaction on singularly primed M13 ssDNA.
(C) Schematic of the 10.1 kbp ARS306 template used for all replication reactions on naked templates. The putative products of bidirectional origin-dependent replication are illustrated.
(D) Standard replication reactions performed on the template illustrated in (C).
(E) Quantitation of pulse-chase experiments performed as in Figure S1 in the presence of Pol δ. Error bars represent the standard error of the mean (SEM) from 3 experiments.
(F) Standard replication reaction with the indicated Pol ε mutants.
Replication products were separated through 0.7% (B) and 1% alkaline agarose gels (D and F).
Figure 2Pol δ Can Access the 3ʹ End of All Nascent Leading Strands
(A) Standard replication reaction with the indicated Pol δ proteins.
(B) Pulse-chase experiment performed as illustrated. When Pol δCat was added during the chase, it was added immediately after the 2.5 min time point.
Products were analyzed through 1% (A) and 0.8% (B) alkaline agarose gels.
Figure 3Mapping Leading-Strand Initiation Sites at ARS306
(A) Schematic of the 5.92 kbp ARS306 template used for chromatin replication reactions. Putative replication products are illustrated, and the locations of the restriction enzymes (distances from the 5′ end of the ACS to the cleavage sites) used to truncate the Left and Right leading-strand products are shown. 5′ cleavage products of variable length will be generated if priming occurs at multiple sites (Right lead illustrated).
(B) Replication reaction (60 min) on the chromatinized template shown in (A). Products were post-replicatively digested with the indicated enzymes and analyzed through a 1% alkaline agarose gel. The undigested sample was loaded twice (lanes 1 and 4) to serve as a marker.
(C) Products from the reaction in (B) were analyzed through a 4% denaturing polyacrylamide gel.
(D) Normalized lane profiles for the data in (C) lanes 3 and 6.
(E) Normalized lane profiles for the data in (C) lanes 2 and 5.
(F) Diagrammatic representation of the data in (D) and (E). Right leading strands (red) are predominantly initiated to the left of the origin and Left leading strands (blue) are mostly initiated to the right. Dotted lines indicate variable start sites for leading-strand replication.
The locations of the ACS and a putative B2 element are highlighted with gray bars. The asterisk indicates that the putative B2 element for ARS306 has been assigned based on a match to a B2 consensus sequence (Chang et al., 2011).
Figure 4Mapping Leading-Strand Initiation Sites at ARS1
(A) Schematic of the 5.76 kbp ARS1 template used for mapping experiments. Expected replication products are illustrated and the locations of the restriction enzymes used to truncate the Left and Right leading-strand products are shown.
(B) Normalized lane profiles for the ARS1 mapping data in Figure S5C in the absence of RNase HII.
The locations of the ACS and B2 element are highlighted with gray bars.
Figure 5Continuous Leading Strands Are Initiated from Lagging-Strand Primers
(A) Experimental design to determine directly whether leading-strand replication is initiated from leading-strand or lagging-strand primers. Delayed addition of Pol α will enable CMG to move away from the origin before synthesis is initiated. If replication is initiated from a leading-strand primer, addition of Pol α after a delay will result in a shortening of leading-strand products. Conversely, if extension of lagging-strand primers from the adjacent replisome is the mechanism used to start leading-strand replication, products will get longer when Pol α addition is delayed.
(B) Reaction scheme for delayed addition of Pol α.
(C) Replication reaction performed as illustrated in (B) on the chromatinized ARS306 template (Figure 3A) for 60 min.
(D) Lane profiles showing the leading-strand replication products in (C).
(E) Initiation-site mapping for the experiment in (C).
Figure 6Replisomes Are Interdependent for Leading-Strand Synthesis Establishment
(A) Illustration of the ARS306 CPD-containing template and the putative replication products if extension of lagging-strand primers is the sole mechanism to establish leading-strand replication.
(B) 60 min replication reaction on undamaged and CPD-containing chromatinized templates. Products were separated through 1% native or denaturing agarose gels as indicated.
(C) Lane profiles of the data in (B), denaturing.
(D) Products from the reaction in (B) were digested with PsiI and separated through a 4% denaturing polyacrylamide gel.
(E) Two-dimensional gel analysis of the products from the CPD-template reaction in (B).
Figure 7Model Describing the Mechanism of Leading-Strand Initiation at Eukaryotic DNA Replication Origins
(i) Following CMG activation, the template is unwound and Pol α is recruited to each replisome to prime on the lagging-strand template.
(ii) Pol δ elongates the primers back across the origin until it catches up with the advancing CMG complexes.
(iii) A polymerase switch occurs, transferring the 3ʹ end of the nascent strand to CMGE. Dashed horizontal arrows illustrate the direction of CMG movement. The colors of the nascent strands correspond to the colors of polymerases that synthesized them.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| 5-alpha Competent | New England Biolabs | Cat# C2987H |
| Novagen | Cat# 71400 | |
| 3X FLAG peptide | Sigma | Cat# F4799 |
| Anti-FLAG M2 affinity gel | Sigma | Cat# A2220 |
| Calmodulin-Sepharose 4B | GE Healthcare | Cat# 17-0529-01 |
| Glutathione Sepharose 4B | GE Healthcare | Cat# 17-0756-01 |
| Talon metal affinity resin | Clontech | Cat# 635502 |
| Ni-NTA Agarose | QIAGEN | Cat# 30210 |
| IgG Sepharose Fast Flow | GE Healthcare | Cat# 17-0969-01 |
| cOmplete, EDTA-free | Roche | Cat# 5056489001 |
| Creatine Phosphate | Sigma | Cat# 27920-1G |
| Creatine Phosphokinase | Sigma | Cat# C7886-3.5KU |
| Sephacryl™ S400 High Resolution | GE Healthcare | Cat# 17-0609-10 |
| Microspin G-50 columns | GE Healthcare | Cat# GE27-5330-02 |
| Isw1a | N/A | |
| Nap1 | N/A | |
| Histones | N/A | |
| FACT | N/A | |
| Nhp6 | N/A | |
| Cdt1-Mcm2-7 | N/A | |
| ORC | N/A | |
| Cdc6 | N/A | |
| DDK | N/A | |
| Sld3/7 | N/A | |
| Cdc45 | N/A | |
| Dpb11 | N/A | |
| Sld2 | N/A | |
| GINS | N/A | |
| Pol ε | N/A | |
| S-CDK | N/A | |
| Mcm10 | N/A | |
| Pol α | N/A | |
| Ctf4 | N/A | |
| RPA | N/A | |
| Topo I | N/A | |
| Mrc1 | N/A | |
| Csm3/Tof1 | N/A | |
| RFC | N/A | |
| PCNA | N/A | |
| Pol δ | N/A | |
| Pol εPIP | This study | N/A |
| Pol εCat | This study | N/A |
| Pol εPIP/Cat | This study | N/A |
| Pol δCat | This study | N/A |
| yCFK1 (Isw1a purification) | N/A | |
| yAM33 (Cdt1-Mcm2-7 purification) | N/A | |
| ySDORC (ORC purification) | N/A | |
| ySDK8 (DDK purification) | N/A | |
| yTD6 (Sld3/7 purification) | N/A | |
| yJY13 (Cdc45 purification) | N/A | |
| yJY26 (Dpb11 purification) | N/A | |
| yTD8 (Sld2 purification) | N/A | |
| yAJ2 (Pol ε purification) | N/A | |
| yAE37 (S-CDK purification) | N/A | |
| yAE95 (Pol α purification) | N/A | |
| yAE40 (Ctf4 purification) | N/A | |
| yAE42 (Topo I purification) | N/A | |
| yJY32 (Mrc1 purification) | N/A | |
| yAE48 (Csm3/Tof1 purification) | N/A | |
| yAE41 (RFC purification) | N/A | |
| yAE34 (Pol δ purification) | N/A | |
| yVA2 | This study | N/A |
| yVA11 (Pol εPIP purification) | This study | N/A |
| yVA7 (Pol εCat purification) | This study | N/A |
| yVA26 (Pol εPIP/Cat purification) | This study | N/A |
| yVA28 (Pol δCat purification) | This study | N/A |
| VA_oligo_1: For including C-terminally 3xFLAG to | This study | N/A |
| VA_oligo_2: For including C-terminally 3xFLAG | This study | N/A |
| VA_oligo_8: For adding D608A mutation in | This study | N/A |
| VA_oligo_9: For adding D608A mutation in | This study | N/A |
| JY_oligo_233: For Pol2 mutation in D640A residue | This study | N/A |
| JY_oligo_234: For Pol-2 mutation in D640A residue | This study | N/A |
| JY_oligo_212: For Pol-2 mutation in F1199A,F1200A | This study | N/A |
| JY_oligo_213: For Pol-2 mutation in F1199A,F1200A | This study | N/A |
| JY_oligo_180: For M13mp18 priming GAATAATGGA | N/A | |
| pBluescript II KS(-) Phagemid | Agilent Technologies | Cat# 212208-51 |
| M13mp18 Single-stranded DNA | New England Biolabs | Cat# N4040S |
| ZN3: ARS306 replication template | N/A | |
| pCFK1: ARS1 replication template | N/A | |
| vVA20: ARS306 replication template | This study | N/A |
| vVA21: ARS306 replication template | This study | N/A |
| vVA22: ARS306 replication template | This study | N/A |
| vJY35: pRS304/Pol2 (D640A), Dpb4-Tev-CBP | This study | N/A |
| vVA1: pRS304/Pol2 (F1199A, F1200A), Dpb4-Tev-CBP | This study | N/A |
| vVA4: pRS304/Pol2 (D640A, F1199A, F1200A), Dpb4-Tev-CBP | This study | N/A |
| vVA5: pRS306/Pol31, Pol3 (D608A) | This study | N/A |
| pCFK1 (Nap1 purification) | N/A | |
| pCDFduet.H2A-H2B (Histones purification) | N/A | |
| pETduet.H3-H4 (Histones purification) | N/A | |
| pRJ1228-Nhp6 (Nhp6 purification) | N/A | |
| pAM3 (Cdc6 purification) | N/A | |
| vJY19 (PCNA purification) | N/A | |
| pJFDJ5 (GINS purification) | N/A | |
| pTF175 (FACT purification) | N/A | |
| pJW22 (FACT purification) | N/A | |
| pJM126 (RPA purification) | Addgene | #49339 |
| pET28a-Mcm10 (Mcm10 purification) | N/A | |
| pBP83 | N/A | |
| ImageJ | National Institute of Health | |
| Prism 7 | GraphPad | |